Streetbeat News

AVDL

Avadel Pharmaceuticals plc

https://www.avadel.com

Industry

Drug Manufacturers - Specialty & Generic

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Open

11.76

Mkt cap

1.1B

Volume

1.6M

High

12.22

P/E Ratio

-15.55

52-wk high

19.09

Low

11.53

Div yield

N/A

52-wk low

10.41

HC Wainwright & Co. has reiterated its Buy rating for Avadel Pharmaceuticals, maintaining a price target of $27.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 10:13 am

Needham analyst Ami Fadia has reiterated a Buy rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and maintained a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 9:53 am

Avadel Pharmaceuticals has received FDA approval for LUMRYZ, an extended-release oral suspension for treating cataplexy or excessive daytime sleepiness in narcolepsy patients aged 7 and older. LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for this condition and has been granted Orphan Drug Exclusivity until 2031.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 1:42 pm

Avadel Pharmaceuticals published data in 'Sleep Medicine' showing the efficacy of LUMRYZ in improving narcolepsy symptoms, regardless of alerting agent use. The Phase 3 REST-ON trial confirmed significant improvements in wakefulness and reduced cataplexy episodes.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 12:10 pm

Needham analyst Ami Fadia has reiterated a Buy rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and maintained a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 10:34 am

Avadel Pharmaceuticals published data from the RESTORE study showing a strong patient preference for their once-nightly LUMRYZ dosing over twice-nightly oxybates for narcolepsy. The study highlights significant benefits in sleep quality and patient satisfaction with LUMRYZ.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 12:21 pm

Needham analyst Ami Fadia has reiterated a Buy rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and maintained a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 9:36 am

HC Wainwright & Co. has reiterated its Buy rating for Avadel Pharmaceuticals, maintaining a price target of $27. Analyst Oren Livnat continues to support the stock, indicating confidence in its potential growth.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 5:25 pm

Avadel Pharmaceuticals announced the publication of a study in Clinical Therapeutics showing that their drug LUMRYZ led to greater weight loss in narcolepsy patients compared to a placebo. This data comes from a post-hoc analysis of the Phase 3 REST-ON clinical trial.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 12:02 pm

Needham analyst Ami Fadia has reiterated a Buy rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and maintained a $22 price target.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 10:19 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.